GBT - GBT STOCK NEWS

Global Blood Therapeutics (GBT) will report its second quarter 2021 financial results on August 3, 2021, after markets close. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss results and provide a business update. GBT is known for its FDA-approved treatment for sickle cell disease, Oxbryta (voxelotor), and is advancing its pipeline with inclacumab in Phase 3 for pain crises and GBT021601 as a next-generation treatment. Visit gbt.com for details.

Global Blood Therapeutics submitted a supplemental New Drug Application to the U.S. FDA for Oxbryta (voxelotor) aimed at treating sickle cell disease in children aged 4-11. The company also initiated Phase 3 clinical trials for inclacumab and enrolled patients in a Phase 1 study of GBT021601. Data from the HOPE-KIDS 1 study indicated that weight-based Oxbryta treatment led to significant hemoglobin improvements. The FDA’s review of the application could lead to a six-month decision timeframe.

Global Blood Therapeutics (GBT) announced on July 1, 2021, that its compensation committee granted options to 23 new employees, allowing them to purchase a total of 9,600 shares of common stock at an exercise price of $37.34. Additionally, restricted stock units for an aggregate of 94,320 shares were awarded. These grants are part of GBT's Amended and Restated 2017 Inducement Equity Plan and comply with NASDAQ Listing Rule 5635(c)(4). Founded in 2011, GBT focuses on developing treatments for sickle cell disease.

Global Blood Therapeutics (GBT) has awarded approximately $450,000 to various U.S. organizations through its 2021 ACCEL Grant Program, aimed at improving care for individuals with sickle cell disease (SCD). This year’s initiatives include projects focusing on COVID-19 vaccine awareness, racial equity, and integrated care delivery. Notable recipients include Cayenne Wellness Center and Massachusetts General Hospital. The program underscores GBT's commitment to enhancing healthcare access for SCD patients and fostering sustainable community care.

Global Blood Therapeutics (GBT) announced that voxelotor has received a Promising Innovative Medicine (PIM) designation from the UK’s MHRA for treating hemolytic anemia in patients 12 years and older with sickle cell disease (SCD). This designation indicates a major potential benefit for patients with a serious unmet need. Voxelotor, previously approved in the US as Oxbryta, addresses the underlying cause of red blood cell sickling. GBT remains committed to advancing voxelotor and applying for further regulatory approvals in Europe.

Global Blood Therapeutics (GBT) announced promising findings from the Phase 2a HOPE-KIDS 1 Study, which showed that children aged 4-11 with sickle cell disease (SCD) treated with Oxbryta experienced significant hemoglobin improvements. In the study, 47% of patients showed an increase in hemoglobin of over 1 g/dL within two weeks of treatment. The results align with prior Phase 3 HOPE Study outcomes for older patients. Additionally, data from real-world studies indicate consistent hemoglobin improvements, reinforcing the medicine's efficacy and safety profile as GBT moves toward broader patient access and ongoing studies in younger demographics.

Global Blood Therapeutics (GBT) has presented new data from the Phase 2a HOPE-KIDS 1 Study, indicating significant hemoglobin improvements in children aged 4-11 with sickle cell disease (SCD) treated with Oxbryta (voxelotor). Notable results include a 47% hemoglobin increase of over 1 g/dL within two weeks and sustained effects for 24 weeks. Additionally, real-world studies showed consistent hemoglobin enhancements, correlating with treatment benefits. GBT emphasizes its commitment to expanding Oxbryta's availability throughout the U.S. and Europe to address critical patient needs.

Global Blood Therapeutics (GBT) has granted stock options and restricted stock units to 11 new employees, as reported on June 1, 2021. The company awarded options to purchase 35,500 shares at $37.20 each and 45,410 restricted stock units under its Amended and Restated 2017 Inducement Equity Plan. These incentives were made as a material inducement for employees joining the company, in compliance with NASDAQ Listing Rule 5635(c)(4). GBT is focused on developing treatments for sickle cell disease, having launched Oxbryta, the first FDA-approved treatment for this condition.

Global Blood Therapeutics (GBT) will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on June 8, 2021, at 2:10 p.m. ET. The event will be accessible via a live webcast on GBT’s website, with a replay available for one month after. GBT focuses on innovative treatments for sickle cell disease, notably the FDA-approved Oxbryta (voxelotor) and ongoing projects like inclacumab and GBT021601. The company's commitment is to transform care for underserved patient communities.